Rubius Therapeutics, Inc.

DB:5RT Stock Report

Market Cap: €1.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Rubius Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Craig Jalbert

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenure2.1yrs

Recent management updates

Recent updates

CEO

Craig Jalbert (61 yo)

less than a year

Tenure

Mr. Craig R. Jalbert, CIRA is President, Treasurer, Corporate Secretary & Director of Aptinyx Inc. since May 04, 2023. He is President, Treasurer, Corporate Secretary, Principal Executive Officer, Interim...

Board Members

NamePositionTenureCompensationOwnership
Craig Jalbert
Presidentless than a yearno datano data
Michael Rosenblatt
Independent Director8.5yrsUS$421.66k0%
€ 0
Robert Langer
Member of Scientific Advisory Board8.5yrsUS$850.74kno data
Harvey Lodish
Scientific Advisory Board5.3yrsUS$24.00kno data
Gerald Nepom
Member of Scientific Advisory Board2.1yrsno datano data
Vijay Kuchroo
Member of Scientific Advisory Board2.1yrsno datano data
Susanne Schaffert
Directorless than a yearno datano data
Francis Cuss
Independent Director5.4yrsUS$426.66k0%
€ 0
Christopher Carpenter
Member of Scientific Advisory Board3.4yrsUS$2.84mno data
Christopher Hunter
Member of Scientific Advisory Board2.1yrsno datano data
John Monroe
Member of Scientific Advisory Board2.1yrsno datano data

2.1yrs

Average Tenure

68yo

Average Age

Experienced Board: 5RT's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/12 17:12
End of Day Share Price 2023/03/15 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rubius Therapeutics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Andrew FeinH.C. Wainwright & Co.
Michael YeeJefferies LLC